SCHEMBL16248659

SCHEMBL16248659

C=P(OC)(OCC)OCCC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16248687 0.88 ALDH1A1 (0.30)
SCHEMBL10158994 0.83
SCHEMBL16193377 0.78 TSHR (0.38)
SCHEMBL14960582 0.76 ACHE (0.31)
SCHEMBL18291793 0.74
SCHEMBL26533819 0.70 TSHR (0.31)
SCHEMBL23772196 0.70
SCHEMBL15977306 0.69 TSHR (0.56)
SCHEMBL7006853 0.69 TSHR (0.56)
SCHEMBL6847124 0.68 TSHR (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-05-18 US disclosed
US-9714421-B2 Compositions and methods IONIS PHARMACEUTICALS, INC. (US) 2017-07-25 US disclosed
US-20170183661-A1 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-29 US disclosed
US-20170166899-A1 COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-15 US disclosed
US-20170159055-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2017-06-08 US disclosed
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2016-07-07 US disclosed
US-9382540-B2 Compositions and methods for modulating angiopoietin-like 3 expression ISIS PHARMACEUTICALS, INC (US) 2016-07-05 US disclosed
US-20160122761-A1 COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 2016-05-05 US disclosed
US-20160090596-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2016-03-31 US disclosed
US-20160090595-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2016-03-31 US disclosed
US-9181550-B2 Compositions and methods for modulating apolipoprotein (a) expression ISIS PHARMACEUTICALS, INC. (US) 2015-11-10 US disclosed
US-20150315594-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-11-05 US disclosed
US-9163239-B2 Compositions and methods for modulating apolipoprotein C-III expression ISIS PHARMACEUTICALS, INC. (US) 2015-10-20 US disclosed
US-9145558-B2 Compositions and methods for modulating HBV expression ISIS PHARMACEUTICALS, INC. (US) 2015-09-29 US disclosed
US-9127276-B2 Conjugated antisense compounds and their use ISIS PHARMACEUTICALS, INC. (US) 2015-09-08 US disclosed
US-20150176007-A1 COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-06-25 US disclosed
US-20150126719-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 US disclosed
US-20150126718-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 US disclosed
US-20150126720-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 US disclosed
US-20140343123-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2014-11-20 US disclosed